Generic Name and Formulations:
Loperamide HCl 2mg; caps.
McNeil Consumer Healthcare
Indications for IMODIUM:
Acute: Initially 4mg, then 2mg after each loose stool; max 16mg/day. Stop after 48 hours if ineffective. Chronic: initially 4mg; maintenance 4–8mg/day. Reevaluate if no improvement after 10 days at 16mg/day.
<2yrs: not recommended. 24–47lbs (2–5yrs): 1mg up to 3 times daily for 2 days (use liq). 48–59lbs (6–8yrs): initially 2mg, then 1mg after each loose stool; max 4mg/day for 2 days. 60–95lbs (9–11yrs): initially 2mg, then 1mg after each loose stool; max 6mg/day for 2 days.
If constipation must be avoided. Acute dysentery.
Acute ulcerative colitis and antibiotic induced pseudomembranous colitis; discontinue if abdominal distention occurs. In dehydration, use fluid and electrolyte replacement. Hepatic dysfunction; monitor for CNS toxicity. Pregnancy (Cat.B). Nursing mothers.
Abdominal pain, distention, constipation, dry mouth, nausea, drowsiness, dizziness, fatigue, rash.
Caps—30; A-D Caplets—6, 12, 18, 24; A-D Liq—2oz, 4oz; Multi-Symptom Caplets—12, 42; Multi-Symptom Chew tabs—18, 42
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds